GILD – gilead sciences, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day GILD SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
1.5%
8/7/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
8.6%
4/24/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
-2.8%
2/11/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
7.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD
SPY
QQQ
SPX
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
1/16
07:02 pm
gild
Low
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]
1/15
05:08 pm
gild
Medium
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
1/15
05:08 pm
gild
Medium
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
1/15
03:59 pm
gild
Neutral
Hopping Mad Over Drug Company Product Hopping [Forbes]
1/15
01:03 pm
gild
Low
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/15
11:16 am
gild
Low
Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]
1/13
11:28 am
gild
Low
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.
1/13
10:59 am
gild
Low
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
1/12
06:13 pm
gild
Low
Gilead Sciences: From All-Time Highs To Higher Highs [Seeking Alpha]
10/30/2025
04:02 pm
gild
1.5%
BEAT
8/7/2025
04:02 pm
gild
8.6%
BEAT
4/24/2025
04:02 pm
gild
-2.8%
BEAT
2/11/2025
04:02 pm
gild
7.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
1/15
01:03 pm
Reiterates
Buy
Buy
UBS Group AG
Low
-1.2%
1/13
11:12 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.0%
1/13
11:12 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.0%
1/13
10:59 am
Reiterates
Outperform
Outperform
BMO Capital Markets
Low
-1.3%
1/7
02:47 pm
Maintains
Buy
Buy
Citigroup
Low
0.9%
1/7
02:47 pm
Maintains
Buy
Buy
Citigroup
Low
0.9%
1/7
08:55 am
Reiterates
Neutral
Buy
UBS Group AG
Low
2.2%
1/7
08:49 am
Assumes
Neutral
Buy
UBS
Low
2.5%
12/15
07:02 am
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
1/16
06:18 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Jan 15 Filed by: Dickinson Andrew D
1/16
06:11 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Jan 15 Filed by: Mercier Johanna
1/15
04:02 pm
gild
Medium
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
1/15
04:02 pm
gild
Medium
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
1/5
05:56 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Jan 02 Filed by: Berger Dietmar
12/30
04:23 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 29 Filed by: O'Day Daniel Patrick
12/29
04:04 pm
gild
Low
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
12/16
06:32 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 15 Filed by: Dickinson Andrew D
12/16
06:13 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 15 Filed by: Mercier Johanna
Show more
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%